SCHEMBL768162

SCHEMBL768162

NCC(O)c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.56
BLM P54132 4/20 0.50
MAPT P10636 3/20 0.50
RECQL P46063 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
TAAR1 Q96RJ0 3/20 0.50
KDM4E B2RXH2 3/20 0.50
HPGD P15428 2/20 0.50
APEX1 P27695 2/20 0.50
ADRB2 P07550 2/20 0.50
ADRB1 P08588 2/20 0.50
ADRB3 P13945 2/20 0.50
LMNA P02545 2/20 0.50
MAPK1 P28482 2/20 0.50
MEN1 O00255 1/20 0.50
ADRA2A P08913 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
DRD2 P14416 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31419997 1.00 PNMT (0.56) PNMTBLMMAPTRECQLTDP1
SCHEMBL3489554 1.00 PNMT (0.56) PNMTBLMMAPTRECQLTDP1
SCHEMBL768007 1.00 PNMT (0.56) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL4465387 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL2327859 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL4802312 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL31332749 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Bicarbonate SCHEMBL9515153 0.93 KDM4E (0.51) PNMTBLMMAPTRECQLTDP1
SCHEMBL10318241 0.85 ADRB2 (0.44) PNMTTAAR1ADRB2ADRB1ADRB3
SCHEMBL1154749 0.83 ADRB3 (0.49) ADRB2ADRB1ADRB3LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5914339-A ANTI-DIABETIC AND/OR ANTIHYPERGLYCEMIA AND/OR ANTI-OBESITY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-06-22 US claimed
US-5236951-A Administering a phenylethanolamine derivative SANOFI (FR) 1993-08-17 US claimed
EP-0403360-A2 Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders SANOFI (FR) 1990-12-19 EP claimed
JP-7112958-A None JP disclosed
JP-10007628-A None JP disclosed
EP-4743460-A1 CRYSTALLINE FORM OF (S)-1-(1- (3-CHLOROPHENYL)-2-(DIMETHYLAMINO) ETHYL)-4- (5 -MORPHOLINO -1H-PYRROLO[2,3-B]PYRIDIN -3-YL)PYRIDIN-2 (1H)-ONE, ITS PREPARATION AND ITS USE AS ERK KINASE INHIBITOR AGV Discovery (FR) 2026-05-20 EP disclosed
EP-4743461-A1 (S)-1-(1- (3-CHLOROPHENYL)-2-(DIMETHYLAMINO) ETHYL)-4-(5 -MORPHOLINO-1H- PYRROLO[2,3-B]PYRIDIN-3-YL) PYRIDIN-2(1H)-ONE,THEIR PREPARATION AND THEIR USE AS ERK KINASE INHIBITORS AGV Discovery (FR) 2026-05-20 EP disclosed
EP-4709708-A1 NOVEL CARBOXAMIDE DERIVATIVES ANGELINI PHARMA S.P.A. (IT) 2026-03-18 EP disclosed
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2026-02-12 US disclosed
WO-2025012386-A1 CRYSTALLINE FORM OF (S)-1-(1-(3-CHLOROPHENYL)-2- (DIMETHYLAMINO)ETHYL)-4-(5-MORPHOLINO-1H-PYRROLO[2,3- B]PYRIDIN-3-YL)PYRIDIN-2(1H)-ONE, ITS PREPARATION AND ITS USE AS ERK KINASE INHIBITOR AGV DISCOVERY (FR) 2025-01-16 WO disclosed
WO-2025012389-A1 SALTS OF (S)-1-(1-(3-CHLOROPHENYL)-2-(DIMETHYLAMINO)ETHYL)-4-(5- MORPHOLINO-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIDIN-2(1H)-ONE, THEIR PREPARATION AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2025-01-16 WO disclosed
US-4309443-A ANTI-OBESITY, HYPOGLYCEMIC BEECHAM GROUP LIMITED (GB) 1982-01-05 US disclosed
EP-0040000-A1 Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions BEECHAM GROUP PLC (GB) 1981-11-18 EP disclosed
EP-0028105-A1 Secondary amines, their preparation and use in pharmaceutical compositions BEECHAM GROUP PLC (GB) 1981-05-06 EP disclosed
EP-0025331-A1 Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1981-03-18 EP disclosed
EP-0023385-A1 Ethanamine derivatives, their preparation and use in pharmaceutical compositions BEECHAM GROUP PLC (GB) 1981-02-04 EP disclosed
EP-0021636-A1 Secondary amines, their preparation and use in pharmaceutical compositions BEECHAM GROUP PLC (GB) 1981-01-07 EP disclosed
US-3983133-A CNS ANTIDEPRESSANTS JANSSEN PHARMACEUTICA N.V. (BE) 1976-09-28 US disclosed
US-3963718-A CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS JANSSEN PHARMACEUTICA (BE) 1976-06-15 US disclosed
US-3947456-A ANTIDEPRESSANTS HOFFMAN-LA ROCHE INC. (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS BRAF, RAF1, NRAS PNMT 3081/4885BLM 4576/4885MAPT 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.